Christina L. Roland, MD, MS, FACS, discusses the results from a phase 2 study evaluating neoadjuvant checkpoint blockade study in patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
Christina L. Roland, MD, PhD
Advertisement
Articles by Christina L. Roland, MD, PhD
Christina L. Roland, MD, MS, FACS, discusses the safety profile of neoadjuvant checkpoint blockade in patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
Christina L. Roland, MD, PhD, discusses the rationale for a phase 2 study evaluating neoadjuvant checkpoint blockade study in patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
Christina L. Roland, MD, PhD, discusses the design of a randomized, phase 2 trial with nivolumab and ipilimumab in resectable retroperitoneal dedifferentiated liposarcoma, as well as radiation therapy in extremity/truncal undifferentiated pleomorphic sarcoma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026
3
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
4
The OncFive: Top Oncology Articles for the Week of 5/31
5